IP Library Granted Patent US 7,524,456
Granted Patent B1
US 7,524,456 · App. 09/613,650 · Granted Apr 28, 2009

Diagnostic devices for the controlled movement of reagents without membranes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,456
App. No.
09/613,650
Granted
Apr 28, 2009
Kind
B1
Abstract

The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.

Claims (26)

1. An assay device for detecting a plurality of target ligands in a sample, comprising:

a nonporous textured surface, said nonporous textured surface comprising one or more depressions or protrusions extending between 1 nm and 0.5 mm from said nonporous textured surface; and

a plurality of discrete capture zones on said surface, each said capture zone comprising receptors immobilized to said surface or immobilized on particles immobilized to said surface, wherein said particle size range is from 1 nm to 5 μm, and wherein said receptors are capable of binding one or more of said plurality of target ligands,

wherein said capture zones occupy one or more discrete hydrophilic regions of said surface delimited by an adjacent hydrophobic region of said surface.

2. An assay device according to claim 1 , wherein each said discrete capture zone comprises receptors independently selected from the group consisting of antibodies, antibody fragments, nucleic acid molecules, and chelators.

3. An assay device according to claim 1 , wherein each said discrete capture zone binds a different target ligand from amongst said plurality of target ligands.

4. An assay device according to claim 3 , wherein said plurality of target ligands are a plurality of nucleic acid molecules, and each said discrete capture zone comprises a nucleic acid molecule having a nucleotide sequence that is complementary to one of said plurality of nucleic acid molecules.

5. An assay device according to claim 3 , wherein each said discrete capture zone comprises an antibody, or a fragment thereof, capable of binding one of said plurality of target ligands.

6. An assay device according to claim 1 , wherein one or more of said discrete capture zones comprise one or more particles immobilized to said surface, wherein said receptors are immobilized on said particles.

7. An assay device according to claim 6 , wherein said receptors are antibodies, or fragments thereof.

8. An assay device according to claim 6 , wherein said surface is a said textured surface, and one or more of said particles are entrapped within depressions and/or between protrusions on the textured surface.

9. An assay device according to claim 6 , wherein said particles are selected from the group consisting of latex particles, silica particles, zirconia particles, alumina particles, titania particles, ceria particles, metal sol particles, and polystyrene particles.

10. An assay device according to any one of claims 1 - 9 , wherein said nonporous surface forms a capillary space between said nonporous surface and a second surface spaced at a capillary forming distance from said nonporous surface.

11. An assay device according to any one of claims 1 - 9 , wherein said nonporous surface is not part of a capillary space.

12. An assay device for detecting a plurality of target ligands in a sample, comprising:

a nonporous textured surface, said nonporous textured surface comprising one or more depressions or protrusions extending between 1 nm and 0.5 mm from said nonporous textured surface; and

a plurality of discrete capture zones on said surface, each said capture zone comprising receptors immobilized thereon to said surface or immobilized on particles immobilized to said surface, wherein said particle size range is from 1 nm to 5 μm, and wherein said receptors are capable of binding one or more of said plurality of target ligands,

wherein said capture zones are located in one more diagnostic elements of said surface, said diagnostic elements being hydrophilic and delimited by one or more adjacent hydrophobic regions of said surface.

13. An assay device according to claim 12 , wherein each said discrete capture zone comprises receptors independently selected from the group consisting of antibodies, antibody fragments, nucleic acid molecules, and chelators.

14. An assay device according to claim 12 , wherein each said discrete capture zone binds a different target ligand from amongst said plurality of target ligands.

15. An assay device according to claim 14 , wherein said plurality of target ligands are a plurality of nucleic acid molecules, and each said discrete capture zone comprises a nucleic acid molecule having a nucleotide sequence that is complementary to one of said plurality of nucleic acid molecules.

16. An assay device according to claim 14 , wherein each said discrete capture zone comprises an antibody, or a fragment thereof, capable of binding one of said plurality of target ligands.

17. An assay device according to claim 12 , wherein one or more of said discrete capture zones comprise one or more particles immobilized to said surface, wherein said receptors are immobilized on said particles.

18. An assay device according to claim 17 , wherein said receptors are antibodies, or fragments thereof.

19. An assay device according to claim 17 , wherein said surface is said textured surface, and one or more of said particles are entrapped within depressions and/or between protrusions on the textured surface.

20. An assay device according to claim 17 , wherein said particles are selected from the group consisting of latex particles, silica particles, zirconia particles, alumina particles, titania particles, ceria particles, metal sol particles, and polystyrene particles.

Assignments (6)
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
SECURITY AGREEMENT Recorded Jul 6, 2007
From: BIOSITE INCORPORATED
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 019523/0276 →
SECURITY AGREEMENT Recorded Jul 5, 2007
From: BIOSITE INCORPORATED
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 019519/0929 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2003
From: BUECHLER, KENNETH F., PH.D.
To: BIOSITE DIAGNOSTICS, INC.
Reel/Frame 014048/0892 →
CHANGE OF NAME Recorded Jun 4, 2003
From: BIOSITE DIAGNOSTICS, INC.
To: BIOSITE, INC.
Reel/Frame 013705/0660 →